

United States District Court
Northern District of California

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
SAN JOSE DIVISION

CAMERON EIDMANN,
Plaintiff,
v.
WALGREEN CO.,
Defendant.

Case No. [5:20-cv-04805-EJD](#)

ORDER GRANTING MOTION TO DISMISS

Re: Dkt. No. 30

In this putative class action, Plaintiff Cameron Eidmann (“Eidmann”) alleges the marketing of Defendant Walgreen Co.’s (“Walgreens”) Infants’ Pain & Fever Acetaminophen is false and misleading and violates California consumer protection statutes. Presently before the Court is Walgreens’ Motion to Dismiss pursuant to Fed. R. Civ. P. 12(b)(6). The Court finds it appropriate to take this motion under submission for decision without oral argument pursuant to Local Civil Rule 7-1(b). For the reasons set forth below, Walgreens’ motion is GRANTED.

I. BACKGROUND

Walgreens is a national drugstore chain that sells brand-name products, as well as Walgreens-branded products, known as “private label” products. Dkt. No. 24, First Amended Complaint (“FAC”) ¶ 2. Among Walgreens’ portfolio of private label goods are over-the-counter pain relievers and fever reducers produced specifically for young children. *Id.* At issue are two private label acetaminophen products—one marketed as Walgreens Infants’ Pain & Fever (“Infants’ Product”) and Children’s Pain & Fever Acetaminophen (“Children’s Product”). *Id.* ¶¶ 2, 5. Prior to the time period at issue in this action, infant and children’s products contained differing acetaminophen concentrations—with infant products containing 80 mg per mL, whereas

Case No.: [5:20-cv-04805-EJD](#)
ORDER GRANTING MOTION TO DISMISS

1 children’s product contained 160 mg per 5 mL of acetaminophen. *Id.* ¶ 17. In 2011,
2 manufacturers instituted an industry-wide effort to prevent accidental infant overdoses by
3 changing the concentration of liquid acetaminophen in infant’s products to be the same as the
4 children’s products at 160 mg per 5 mL. *Id.* ¶ 22.

5 In line with this industry standard, Walgreens Infants’ Product and Children’s Product
6 have the same concentration of acetaminophen listed on the front of their respective packaging.
7 *Id.* ¶ 23. Both packages also display the age ranges for the products with Infants’ Product listing
8 “Ages 2-3 Years” and Children’s Product listing “Ages 2-11 Years.” Dkt. No. 32 (“Walgreens
9 RJN”), Exh. 7.¹ The products are distinguished by the depictions of the dosing mechanism. The
10 Infants’ Product displays a drawing of a syringe with the instruction to “Use only with enclosed
11 syringe,” whereas the Children’s product only displays a depiction of a dosing cup. *Id.* The
12 following are images of the product packaging:



13
14
15
16
17
18
19
20
21
22
23
24
25 *Id.*

26
27 ¹ As discussed below, the Court grants Walgreens’ unopposed Request for Judicial Notice of the
28 product packaging pursuant to Federal Rule of Evidence 201(b).
Case No.: [5:20-cv-04805-EJD](#)
ORDER GRANTING MOTION TO DISMISS

1 Eidmann alleges that Walgreens “has been engaging in the unfair, unlawful, and deceptive
2 practice of manufacturing, marketing and selling its store brand pediatric acetaminophen as two
3 separate products.” FAC ¶ 25. This deception thus leads consumers to believe the Infants’
4 Product is specially formulated for infants since neither label indicates “that the formulation of the
5 two medicines is entirely identical.” *Id.* ¶ 30. As a result, consumers are injured because “the
6 Infants’ Product can cost almost four times as much per ounce than the Children’s Product, despite
7 being identical medicines.” *Id.* ¶ 31.

8 In the summer of 2020, Eidmann filed his first complaint. Several months later, Walgreens
9 filed a motion to dismiss. Dkt. No. 19. In lieu of filing a response, Eidmann filed the operative
10 First Amended Complaint. Dkt. No. 24 (“FAC”). The FAC asserts four causes of action: (1)
11 violations of the California False and Misleading Advertising Law (FAL); (2) violations of
12 California’s Consumer Legal Remedies Act (CLRA); (3) violation of the unfair and fraudulent
13 prong of California’s Unfair Competition Law (UCL), and (4) violation of the unlawful prong of
14 the UCL. *Id.* Shortly after, Walgreens filed the instant motion to dismiss the FAC. Dkt. No. 30
15 (“Mot.”). Eidmann filed an opposition. Dkt. No. 34 (“Opp.”). Walgreens filed a reply. Dkt. No.
16 36 (“Reply”).

17 **II. LEGAL STANDARD**

18 A motion to dismiss under Fed. R. Civ. P. 12(b)(6) tests the legal sufficiency of claims
19 alleged in the complaint. *Parks Sch. of Bus., Inc. v. Symington*, 51 F.3d 1480, 1484 (9th Cir.
20 1995). When deciding whether to grant a motion to dismiss, the court must generally accept as
21 true all “well-pleaded factual allegations.” *Ashcroft v. Iqbal*, 556 U.S. 662, 664 (2009). The court
22 must also construe the alleged facts in the light most favorable to the plaintiff. *See Retail Prop.*
23 *Trust v. United Bhd. of Carpenters & Joiners of Am.*, 768 F.3d 938, 945 (9th Cir. 2014) (providing
24 the court must “draw all reasonable inferences in favor of the nonmoving party” for a Rule
25 12(b)(6) motion). Dismissal “is proper only where there is no cognizable legal theory or an
26 absence of sufficient facts alleged to support a cognizable legal theory.” *Navarro v. Block*, 250
27 F.3d 729, 732 (9th Cir. 2001).

1 Consumer-protection claims that sound in fraud, as Eidmann’s do, are subject to the
2 heightened pleading requirements of Fed. R. Civ. P. 9(b). *Vess v. Ciba-Geigy Corp. USA*, 317
3 F.3d 1097, 1102 (9th Cir. 2003); *see also Kearns v. Ford Motor Co.*, 567 F.3d 1120, 1125 (9th
4 Cir. 2009). Rule 9(b) requires that “a party must state with particularity the circumstances
5 constituting fraud.” Fed. R. Civ. P. 9(b). The circumstances constituting the fraud must be
6 “specific enough to give defendants notice of the particular misconduct which is alleged to
7 constitute the fraud charged so that they can defend against the charge and not just deny that they
8 have done anything wrong.” *Semegen v. Weidner*, 780 F.2d 727, 731 (9th Cir. 1985). Therefore,
9 a party alleging fraud must set forth “the who, what, when, where, and how” of the misconduct.
10 *Vess*, 317 F.3d at 1106 (quoting *Cooper v. Pickett*, 137 F.3d 616, 627 (9th Cir. 1997)).

11 **III. DISCUSSION**

12 **A. Judicial Notice**

13 Before addressing the merits of the motion, the Court first considers Walgreens’ request
14 for judicial notice, and Eidmann’s request for judicial notice, Dkt. No. 35 (“Eidmann RJN”).

15 As a general rule, the Court may not consider any material outside the pleadings in ruling
16 on a Rule 12(b)(6) motion. *United States v. Corinthian Colleges*, 655 F.3d 984, 998 (9th Cir.
17 2011). There are two exceptions to this rule: when the complaint necessarily relies on the
18 documents (incorporation by reference), and when the documents are “matters of public record”
19 under Fed. R. Evid. 201(b). *Lee v. City of Los Angeles*, 250 F.3d 668, 689 (9th Cir. 2001). The
20 incorporation by reference doctrine allows for the consideration of material that is attached to the
21 complaint, as well as for the consideration of “unattached evidence on which the complaint
22 ‘necessarily relies’ if: (1) the complaint refers to the document; (2) the document is central to
23 plaintiff’s claim; and (3) no party questions the authenticity of the document.” *Corinthian*
24 *Colleges*, 655 F.3d at 999.

25 Under the Federal Rules, a court may also take judicial notice of a fact that is “not subject
26 to reasonable dispute in that it is either (1) generally known within the territorial jurisdiction of the
27 trial court or (2) capable of accurate and ready determination by resort to sources whose accuracy

1 cannot reasonably be questioned.” Fed. R. Evid. 201(b).

2 Both parties submit documents from similar sources, so the Court will consider them
3 together. Neither party has opposed the requests for judicial notice.

4 **i. Public Records**

5 Walgreens requests judicial notice of regulations promulgated by the Food and Drug
6 Administration (“FDA”). Walgreens RJN, Exh. 1. Documents published in the Federal Register
7 are proper for judicial notice. *See* 44 U.S.C. § 1507 (“The contents of the Federal Register shall
8 be judicially noticed). Therefore, the Court GRANTS Walgreens’ Request for Judicial Notice as
9 to the FDA regulations.

10 **ii. Documents from Government Website**

11 Walgreens requests judicial notice of information related to the concentration of
12 acetaminophen in infant medicine published on the FDA website. Walgreens RJN, Exh. 2-4.
13 Likewise, Eidmann requests judicial notice of FDA webpages related to the regulatory process for
14 over-the-counter drugs. Eidmann RJN, Exh. 1-2.

15 Documents published on government-run websites are proper for judicial notice given their
16 reliability. *See Daniels-Hall v. Nat’l Educ. Ass’n*, 629 F.3d 992, 998 (9th Cir. 2010) (appropriate
17 to take judicial notice of information made publicly available by government entities and where
18 neither party disputes the authenticity of the website source); *Gerritsen v. Warner Bros. Entm’t*
19 *Inc.*, 112 F. Supp. 3d 1011, 1034 (C.D. Cal. 2015) (profiles on California Secretary of State
20 website proper for judicial notice).

21 Since both parties’ documents were published to the FDA website, coupled with the fact
22 that neither party contests the accuracy of the documents, the Court will take judicial notice of the
23 FDA webpages submitted by Walgreens and Eidmann.

24 **iii. Photo Images of Product Labels**

25 Walgreens further seeks judicial notice of three images: (1) the product label for Infants’
26 Product, (2) the product label for Children’s Product, and (3) a side-by-side comparison of the two
27 images. Walgreens RJN, Exh. 5-7.

1 Exhibits 5-7 meet the standard for judicial notice under the doctrine of incorporation by
2 reference. Eidmann makes numerous references to both product labels in the Amended
3 Complaint. *See* Compl. ¶¶ 26-28. Moreover, the labels are central to Eidmann’s claims because it
4 is the information conveyed on the Infants’ Product packaging that Eidmann alleges was false or
5 misleading. *Id.* ¶ 35. Importantly, Eidmann does not dispute the authenticity of the product
6 labels. Therefore, the Court GRANTS Walgreens’ Request for Judicial Notice regarding Exhibits
7 5-7.

8 **iv. Court Filings**

9 The final materials requested for judicial notice by Walgreens are court orders from three
10 cases in the Northern and Central Districts of California: *Danielle Lokey v. CVS Pharmacy, Inc.*,
11 Case No. 3:20-cv-04782-LB; *Rony Elkies, et al. v. Johnson and Johnson Services, Inc. et al*, Case
12 No. 2:17-cv-07320-GW-JEM, and *Brian Youngblood, et al v. CVS Pharmacy*, Case No. 2:20-cv-
13 06251-MCS-MRW. Walgreens RJN, Exh. 8-13. Pursuant to Civil Local Rule 3-4, this Court may
14 consider the orders and opinions of federal courts—even those solely available on an electronic
15 database—as long as the order is not designated “Not For Citation” under Civil Local Rule 7-14 or
16 similar rules of other jurisdictions. Thus, the Court may consider these cases as persuasive
17 authority, but need not grant judicial notice of the orders.

18 Accordingly, the Court DENIES Walgreens’ Request for Judicial Notice regarding
19 Exhibits 8-13.

20 **B. Claims Under the FAL, CLRA, and UCL**

21 Eidmann asserts four causes of action against Walgreens: (1) violation of California’s
22 FAL; (2) violation of the CLRA; (3) violation of the fraudulent and unlawful prongs of the UCL;
23 and (4) violation of the unfair prong of the UCL.

24 The FAL prohibits false advertising by making it unlawful to disseminate to the public any
25 information related to disposal of goods or performance of services that “is untrue or misleading,
26 and which is known, or . . . should be known, to be untrue or misleading.” Cal. Bus. & Prof. Code
27 § 17500. Similarly, the CLRA prohibits specific “unfair methods of competition and unfair or

1 deceptive acts . . . intended to result or that results in the sale or lease of goods or services to any
2 customer.” Cal. Civ. Code §1770(a).

3 The UCL provides a cause of action for “any unlawful, unfair, or fraudulent business act or
4 practice.” Cal. Bus. & Prof. Code § 17200. Each of these “prongs” under the UCL creates an
5 independent theory of liability. *Hadley v. Kellogg Sales Co.*, 243 F. Supp. 3d 1074, 1089 (N.D.
6 Cal. 2017). Eidmann asserts claims under each of these prongs of the UCL. The Court will
7 therefore address these three prongs separately.

8 Eidmann grounds his claims under the FAL, CLRA, and UCL on the theory that
9 Walgreens’ packaging and marketing of the Infants’ Product misled customers into believing the
10 product is specially formulated for infants, thereby inducing customers into paying a premium
11 price. Because Eidmann’s allegations rest upon this unified theory, all of his claims must “rise or
12 fall together.” *Id.* Therefore, the Court will consider these three causes of action together.

13 **i. Fraud-Based Claims under FAL, CLRA, and UCL**

14 Conduct that is considered deceptive or misleading runs afoul of the FAL, CLRA, and
15 fraudulent prong of the UCL when it is “likely to deceive” a “reasonable consumer.” *Williams v.*
16 *Gerber Prods. Co.*, 552 F.3d 934, 938 (9th Cir. 2008). Because each of these statutes is governed
17 by the “reasonable consumer” test, courts tend to analyze the three statutes together. *See Hadley*,
18 243 F. Supp. 3d. at 1089; *Fitzhenry-Russell v. Coca-Cola Co.*, No. 5:17-CV-00603-EJD, 2017 WL
19 4680073, at *3 (N.D. Cal. Oct. 18, 2017). The reasonable consumer standard “requires a
20 probability ‘that a significant portion of the general consuming public . . . could be misled.’”
21 *Ebner v. Fresh, Inc.*, 838 F.3d 958, 965 (9th Cir. 2016) (citing *Lavie v. Procter & Gamble Co.*,
22 105 Cal. App. 4th 496, 129 Cal. Rptr. 2d 486, 495 (2003)).

23 Walgreens argues that Eidmann cannot show a reasonable consumer would be deceived by
24 the Infants’ Product. Mot. at 9. In support, Walgreens relies on a similarly situated case decided
25 recently in the Northern District of California. *Lokey v. CVS Pharmacy, Inc.*, No. 20-CV-04782-
26 LB, 2020 WL 6822890, at *1 (N.D. Cal. Nov. 20, 2020). In *Lokey*, the court granted defendant
27 CVS’s motion to dismiss the plaintiff’s claims that CVS’s private label infant acetaminophen

1 violated the FAL, CLRA, and UCL. *Id.* Notably, the plaintiff’s claims in *Lokey* were remarkably
2 similar to this case, alleging that the CVS-brand product “deceives reasonable consumers . . . into
3 believing that Infants’ acetaminophen is specially formulated for children under two and that
4 customers should pay vastly more” than they pay for the identically formulated children’s
5 acetaminophen product. *Id.* at *2. In its analysis, the Court compared the two products’
6 packaging and ultimately concluded that “the labels here are not deceptive.” *Id.* at 5. In reaching
7 its decision, the Court explained:

8 The labels here are not deceptive. The front label shows that the
9 medicines are compositionally the same. The products have different
10 devices to deliver the doses (a syringe for infants and a cup for
11 children), also displayed on the front label. The pictures (a child of
12 indeterminate age on the infants’ label and an older child on the
13 children’s label) or the dosing instructions do not plausibly suggest
14 different formulations, given the front-label representation about the
15 composition of the medicines. In sum, nothing on the labels is
16 deceptive, and the plaintiff’s subjective belief of deception fails the
17 reasonable-consumer test . . . Because the label is not deceptive, and
18 the plaintiff’s subjective interpretation fails the reasonable-consumer
19 test, the plaintiff’s challenge to the differential pricing fails.

20 *Lokey*, 2020 WL 6822890, at *5 (N.D. Cal. Nov. 20, 2020) (citations omitted).

21 There are several similarities between the products at issue here and those at issue in
22 *Lokey*. First, the acetaminophen concentration on the Infants’ Product and Children’s Product is
23 prominently listed in bolded lettering as “160 mg per 5 mL” on the front of the package.
24 Walgreens RJN, Exh. 7. In addition, the concentration is also listed in bold lettering on top of the
25 packaging and in highlighted text in the “Drug Facts” section on the back of the packaging.
26 Walgreens RJN, Exh. 5. Second, the Walgreens packaging indicates the inclusion of the
27 medicine’s dosing mechanism—a syringe for infants and a cup for children. Walgreens RJN, Exh.
28 7. In particular, the front of the Infants’ Product packaging instructs consumers to “use only with
enclosed syringe.” Walgreens RJN, Exh. 5. Moreover, the side of the packaging notes the
“enclosed syringe [is] specifically designed for use with this product.” *Id.* Thus, the infant-
specific branding is less suggestive of a formulation specially designed for infants, as Eidmann
alleges, rather it more reasonably pertains to the infant-specific dosing mechanism included to
administer the product.

1 The differences between the Walgreens products at issue here and the CVS products in
2 *Lokey* are also instructive. Unlike in *Lokey*, Walgreens’ Infants’ Product discloses the intended
3 age range as “ages 2-3 years,” which overlaps with the age range indicated on the Children’s
4 Product, which is “ages 2-11 years.” *Id.* Therefore, a consumer could readily compare the
5 products and find not only that they contain the same acetaminophen concentration, but also that
6 they can be used by children of identical ages. Moreover, the depictions of children on the
7 Infants’ Product and Children’s Product are cartoon-like illustrations, not photographs. *Id.* It is
8 hard to imagine that a reasonable consumer would believe the medicine is specially formulated for
9 infants based on an illustration, especially one so simplistically one-dimensional as the one on the
10 Infants’ Product. *See Werbel ex rel. v. Pepsico, Inc.*, No. C 09-04456 SBA, 2010 WL 2673860, at
11 *3 (N.D. Cal. July 2, 2010) (cartoon depictions of Cap’n Crunch “Crunch Berries” belies any
12 suggestion the cereal “has some nutritional value derived from fruit”).

13 Nevertheless, Eidmann argues that the court in *Lokey* “got it wrong” and this Court should
14 instead rely upon two cases from the Central District of California—*Elkies v. Johnson & Johnson*
15 *Servs, Inc.*, No. 17-cv-07320-GW, ECF No. 53 (C.D. Cal. Feb. 22, 2018), and *Youngblood v.*
16 *CVS*, No. 2:20-cv-06251-MCS-MRW, ECF No. 31 (C.D. Cal. Oct. 15, 2020). *Opp.* at 7, n.3.
17 Both cases follow similar contours: plaintiffs claimed infant acetaminophen products deceived
18 customers into paying higher prices for a drug with the exact formulation as its cheaper, children’s
19 formula counterpart. However, both cases are readily distinguishable from the case at hand.

20 In *Elkies*, the court considered the packaging of infant and children’s Tylenol products and
21 found that the “[d]efendants also purposefully package Infants’ with a picture of a mother holding
22 her young baby under the word ‘Infants,’ with no age range listed, while Children’s contains a
23 mother hugging her significantly older child under the description ‘Ages 2-11 Years.’” *Elkies*,
24 No. 17-cv-07320, at 2. Based on these depictions and no “express disclosure that the medicine in
25 the bottle is exactly the same, and provided at the exact same concentration,” the court denied the
26 motion to dismiss. *Id.* at 8.

27 In *Youngblood*, the court built on the decision in *Elkies* by addressing a CVS-branded

1 infant acetaminophen product that was similar to the Tylenol product in *Elkies*, but which
2 disclosed the identical concentration of acetaminophen. *Youngblood*, 2:20-cv-06251, at 7.
3 Despite these disclosures, the *Youngblood* court held that plaintiffs plausibly alleged the
4 packaging could be misleading. *Id.* at 8. In particular, the court found the photograph depictions
5 “of what appears to be a mother holding a young child [on the Infants’ Product] relative to the
6 older child featured on the Children’s Product” to be dispositive. *Id.* at 7. These photographs on
7 the front of the CVS packages, coupled with the fact “the Product prominently suggests that it is
8 for ‘infants’” ultimately cut against defendant’s claims that no reasonable consumer would be
9 misled to believe the product was specifically formulated for infants. *Id.*

10 In this case, however, neither of the determinative factors of *Elkies* or *Youngblood* are
11 present. The Walgreens Infants’ Product displays overlapping age ranges and identical
12 acetaminophen concentration information in large print on the front of the box. *Cf. Mullins v.*
13 *Premier Nutrition Corp.*, 178 F. Supp. 3d 867, 892 (N.D. Cal. 2016) (inclusion of ingredients list
14 does not shield manufacturers since it is not reasonable to expect consumers to discover truth in
15 fine print on side of the box). Moreover, the pictures on the Walgreens label are stylized cartoon-
16 like depictions of children, unlike the photographs on the products at issue in *Elkies* and
17 *Youngblood*. Nevertheless, Eidmann argues the inclusion of the word “infants” in the name would
18 lead a reasonable consumer to construe the product as specially formulated for infants. *Opp.* at 8
19 (citing *Mullins*, 178 F. Supp 3d at 891 (“[Defendant] cannot run from the fact that it sells Joint
20 Juice. The name alone implies that the whole point to drinking the product is to receive joint
21 health benefits.”)). However, *Mullins* is readily distinguishable from this case. In *Mullins*, the
22 plaintiff claimed the health drink’s name and packaging was false and misleading because it
23 implied the beverage would “relieve joint pain and stiffness.” *Id.* at 889. Here, Eidmann does not
24 dispute the effectiveness of Infants’ Product to quell pain and reduce fevers in infants. Rather, he
25 asserts the product name further implies that the medicine is specially formulated for infants. The
26 Court finds this rationale unpersuasive. No reasonable consumer would understand Infants’
27 Product to be specially formulated, in light of the numerous express statements regarding the

1 acetaminophen concentration, overlapping age ranges, and the infant-specific dosing mechanism.
 2 *See Dinan v. Sandisk LLC*, No. 18-CV-05420-BLF, 2019 WL 2327923, at *7 (N.D. Cal. May 31,
 3 2019) (“What ultimately dooms Plaintiff’s claims is that Defendant tells the consumer exactly
 4 what she is getting”).

5 Walgreens further argues that, barring any finding that the packaging is misleading,
 6 Eidmann’s claims “amount to nothing more than a complaint about pricing differences.” Mot. at
 7 16. Eidmann, however, contends the pricing information itself is not deceptive, rather it is
 8 evidence of “how Plaintiff and the Class were economically injured.” Opp. at 10. As a general
 9 matter, “price regulation is a political question beyond the judiciary’s authority.” *Boris v. Wal-*
 10 *Mart Stores, Inc.*, 35 F. Supp. 3d 1163, 1172 (C.D. Cal. 2014), *aff’d*, 649 F. App’x 424 (9th Cir.
 11 2016). In *Boris*, the court considered Wal-Mart’s marketing of two over-the-counter headache
 12 medications with identical active ingredients, which were differentiated by their names, prices,
 13 and the background color on the packaging. *Id.* at 1165. The *Boris* plaintiffs alleged the “price
 14 differential along with [Equate Migraine’s] red background ‘deceived [consumers]’” into thinking
 15 it was more effective than it’s “Extra Strength” counterpart. *Id.* However, the court dismissed the
 16 plaintiff’s FAL, CLRA, and UCL claims because the packaging and price differentials were not
 17 deceptive. *Id.* at 1170. Absent any deception by the defendant, the *Boris* court refused to
 18 adjudicate Wal-Mart’s pricing decisions. *Id.* at 1172. In this case, as in *Boris*, Eidmann has failed
 19 to show how Walgreens’ marketing of Infants’ Product is false and misleading. Therefore,
 20 Eidmann cannot challenge Walgreens’ pricing decisions.

21 Based on the foregoing, it is not plausible that a “significant portion of the general
 22 consuming public” would be misled to believe that Infants’ Product is specially formulated for
 23 infants. *Ebner*, 838 F.3d at 965. Therefore, Eidmann has failed to state a claim that Infants’
 24 Product is misleading or deceptive under the FAL, CLRA, and fraudulent prong of the UCL.

25 **ii. Fraudulent Omission Claims**

26 In addition to alleged misrepresentations above, Eidmann also asserts violations of the
 27 FAL, CLRA, and UCL based upon an omission theory. *See* FAC ¶¶ 81, 92, 101. Eidmann argues

1 that Walgreens failed to expressly state that the Infants' Product and Children's Product contain
2 identical formulations, which he alleges is contrary to the "affirmative representations . . . that the
3 Infants' Product is *for infants*." Opp. at 9. Eidmann further argues that Walgreens was obligated
4 to disclose this information to consumers. *Id.*

5 A plaintiff may base a claim on an alleged omission if the omitted fact is (1) contrary to a
6 [material] representation actually made by the defendant or (2) is a fact the defendant was
7 obligated to disclose. *Sud v. Costco Wholesale Corp.*, 229 F.Supp.3d 1075, 1085 (N.D. Cal. 2017)
8 (quoting *Daugherty v. Am. Honda Motor Co.*, 144 Cal.App.4th 824, 835, 51 Cal.Rptr.3d 118
9 (2006)). Thus, under this latter omission theory, there must be a duty to disclose the omitted facts
10 "even in the absence of a particular representation." *Beyer v. Symantec Corp.*, 333 F. Supp. 3d
11 966, 978 (N.D. Cal. 2018). The duty to disclose arises when: (1) when the defendant is the
12 plaintiff's fiduciary; (2) when the defendant has exclusive knowledge of material facts not known
13 or reasonably accessible to the plaintiff; (3) when the defendant actively conceals a material fact
14 from the plaintiff; and (4) when the defendant makes partial representations that are misleading
15 because some other material fact has not been disclosed. *Hodson v. Mars, Inc.*, 891 F. 3d 857, 862
16 (9th Cir. 2018) (citing *LiMandri v. Judkins*, 52 Cal. App. 4th 326, 336, 60 Cal.Rptr.2d 539
17 (1997)).

18 Under the first omission theory, Eidmann claims "Walgreens affirmatively states and
19 implies that the Product is unique and/or specially designed and formulated for infants," and that
20 Walgreens' failure to disclose the allegedly contrary information that Infants' and Children's
21 Products contained the same formula constitutes a fraudulent omission. Opp. at 9. However,
22 Eidmann cannot point to any affirmative statements that Infants' formula is unique or distinct
23 from Children's. Moreover, for all the reasons stated above, the Court does not find that the
24 packaging implies an infant-specific formulation, especially considering the numerous
25 representations on the packaging that *do* state the identical formulations. Therefore, Eidmann's
26 argument fails because the allegedly omitted fact is not contrary to any of the representations on
27 the Infants' Product packaging.

1 Turning to the second omission theory, Eidmann fails to adequately plead that Walgreens
2 has a duty to disclose that the Infants' Product is identical to the Children's Product. Eidmann
3 does not put forth any facts to establish a fiduciary relationship between himself and Walgreens.
4 More importantly, Eidmann cannot show the allegedly omitted information is within the exclusive
5 knowledge of Walgreens. Indeed, there are numerous disclosures on the packaging that would
6 allow consumers to ascertain that the products contain identical formulations. Because Eidmann
7 fails to allege that Walgreens is under an obligation to disclose this information, his claims under
8 this omission theory also fail.

9 Based on the foregoing, the Court GRANTS Walgreens' motion to dismiss Eidmann's
10 claims under the FAL, CLRA, and UCL based on fraudulent omission theories.

11 **iii. The Unlawful and Unfair Prongs of the UCL**

12 Eidmann further alleges the violations of the FAL, CLRA, and UCL "constitute predicate
13 acts which violate the UCL's 'unlawful prong.'" FAC ¶ 117. However, a claim under this prong
14 hinges upon whether a plaintiff can formulate a claim under the predicate law. *Hadley*, 243 F.
15 Supp. 3d at 1094. Thus, if the "plaintiff cannot state a claim under the predicate law . . . [the
16 UCL] claim also fails." *Id.* (citing *Stokes v. CitiMortgage, Inc.*, 2014 WL 4359193, at *11 (C.D.
17 Cal. Sept. 3, 2014)). Moreover, when the claim under the UCL unlawful prong is grounded in
18 fraud, the plaintiff must meet the heightened pleading standard under Rule 9(b). *Wilson v. Frito-*
19 *Lay N. Am., Inc.*, No. 12-1586 SC, 2013 WL 1320468, at *5 (N.D. Cal. Apr. 1, 2013).

20 Eidmann bases his unlawful arguments on the same alleged conduct the Court found
21 inadequate under the fraudulent misrepresentation and omission theories above. Because Eidmann
22 failed to allege violations of the FAL, CLRA, and UCL pursuant to Rule 9(b), he is precluded
23 from utilizing these violations as predicate acts under the unlawful prong of the UCL.

24 Likewise, Eidmann's claim under the unfair prong of the UCL fails for similar reasons. In
25 this District, when plaintiff's claim under the unfair prong overlaps entirely with the conduct
26 alleged in the fraudulent and unlawful prongs of the UCL, "the unfair prong of the UCL cannot
27 survive if the claims under the other two prongs . . . do not survive." *Hadley*, 243 F. Supp. 3d at

1 1105. Here, Eidmann alleges Walgreens’ practices “are unfair because . . . he was deceived into
2 thinking Infants’ was specially formulated.” FAC ¶ 105. This claim consists entirely of the
3 allegations also proffered to support Eidmann’s claim under the fraudulent prong of the UCL. *See*
4 FAC ¶ 104. Therefore, for the same reasons the Court granted Walgreens’ motion to dismiss
5 claims under the fraudulent and unlawful prongs of the UCL, the Court GRANTS Walgreens’
6 motion to dismiss Eidmann’s claim under the unlawful prong of the UCL.

7 **IV. CONCLUSION**

8 For the reasons set forth above, the Court GRANTS Walgreens’ Motion to Dismiss all
9 claims under the FAL, CLRA, and UCL.

10 Under Federal Rule of Civil Procedure 15(a), leave to amend “should be freely granted when
11 justice so requires.” When dismissing a complaint for failure to state a claim, a court should grant
12 leave to amend “unless it determines that the pleading could not possibly be cured by the
13 allegation of other facts.” *Lopez v. Smith*, 203 F.3d 1122, 1127 (9th Cir. 2000). The Court finds
14 that leave to amend would be futile in this case for several reasons. First, Eidmann has already
15 had the opportunity to amend his claims in the FAC. Second, because the Court’s analysis is
16 based in large part on the express disclosures on the Infants’ Product packaging, which are
17 undisputed, there are no further facts Eidmann can allege to cure the complaint. For these reasons,
18 Eidmann’s claims are dismissed with prejudice.

19 **IT IS SO ORDERED.**

20 Dated: February 26, 2021



EDWARD J. DAVILA
United States District Judge